Effects of intravenous human albumin, enteral cilostazol, and combination therapy on the reduction of delayed cerebral ischemia in patients with aneurysmal subarachnoid hemorrhage - Report - MDSpire
Advertisement
Effects of intravenous human albumin, enteral cilostazol, and combination therapy on the reduction of delayed cerebral ischemia in patients with aneurysmal subarachnoid hemorrhage
Impact of Intravenous Human Albumin, Enteral Cilostazol, and Their Combined Use
Overview
This study evaluates the effects of intravenous human albumin, enteral cilostazol, and their combination on reducing delayed cerebral ischemia (DCI) in patients with aneurysmal subarachnoid hemorrhage (aSAH).
Background
Delayed cerebral ischemia (DCI) is a significant cause of morbidity and mortality following aneurysmal subarachnoid hemorrhage (aSAH). Current treatment options are limited, with oral nimodipine being the only agent proven to improve neurological outcomes.
Data Highlights
Treatment
Median ARR vs Control (%)
90% Simulation Interval
Prior-Predictive Probability of ARR > 0 (%)
Albumin
9.1
−3.3 to 18.1
89.8
Cilostazol
18.1
11.0 to 25.4
99.9
Combination Therapy
21.7
12.4 to 29.9
99.8
Key Findings
The median absolute risk reduction (ARR) for DCI was 9.1% for albumin, 18.1% for cilostazol, and 21.7% for combination therapy.
The incremental benefit of adding albumin to cilostazol was small and uncertain at 3.5%.
Simulation results indicate a high probability of cilostazol and combination therapy being effective in reducing DCI.
Sample sizes for trials would need to be substantial, with illustrative sizes of 343 for albumin and 49 for combination therapy.
Current evidence for cilostazol is stronger than for albumin based on previous studies.
Clinical Implications
Continued randomized evaluations are necessary to better understand the efficacy of these treatments and their potential interactions.
Conclusion
Further research is warranted to explore the effects of cilostazol and albumin in aSAH management.
The largest study of former National Football League players found excess persisted even after accounting for the lower overall mortality associated with elite athletic participation.
